Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Abacus Life, Inc. (ABL) shares ended the last trading session 5.4% higher at $10.40. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.1% loss over the past four weeks.ABL stays focused on consolidating its position as a leading market maker and global alternative asset manager.  The strength of partnerships with carriers and reinsurers remains a key contributor to its performance. Also, along with core business o ...

Core Viewpoint - Abacus Life, Inc. (ABL) shows potential for upside based on Wall Street analysts' price targets, with a mean estimate of $14 indicating a 34.6% increase from the current price of $10.40 [1] Price Targets and Analyst Consensus - The mean price target consists of three estimates with a standard deviation of $2, suggesting a consensus among analysts [1] - The lowest estimate of $12 indicates a 15.4% increase, while the highest estimate of $16 suggests a 53.9% increase [1] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [4] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ABL's earnings prospects, as indicated by upward revisions in EPS estimates [5] - The Zacks Consensus Estimate for the current year has increased by 4.3%, with one estimate moving higher and no negative revisions [5] - ABL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors [5] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [2][3] - Price targets can often mislead investors, and while they should not be ignored, they should be approached with skepticism [4]

ORLANDO, Fla., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading global alternative asset manager focused on lifespan-based financial products, today announced that its popular Abacus Policy Value Calculator, which recently launched its newest generation, has surpassed 150,000 individual submissions from insureds, totaling more than $87 billion in face value. “Since the original version of the calculator, we have been proud to provide over 150,000 insu ...

ORLANDO, Fla., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading global alternative asset manager focused on lifespan-based financial products, today announced that Corey McLaren has joined Abacus as Managing Director, Capital Markets. Based in Boston, Mr. McLaren has almost two decades of experience in financial services, including over fifteen years of business development and management experience directly related to life settlements. Mr. McLaren mo ...

Abacus Life, Inc. (ABL) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in ear ...

Group 1: Stock Performance and Price Targets - Abacus Life, Inc. (ABL) shares have increased by 3.7% over the past four weeks, closing at $10.30, with a mean price target of $13.67 indicating a potential upside of 32.7% [1] - The average price target consists of three estimates ranging from $12 to $15, with a standard deviation of $1.53, suggesting a relatively high agreement among analysts [1][4] - The lowest estimate suggests a 16.5% increase, while the highest points to a 45.6% upside [1] Group 2: Analyst Sentiment and Earnings Estimates - Analysts show strong agreement regarding ABL's ability to report better earnings than previously predicted, which supports the potential for stock upside [2][5] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 7.6%, with no negative revisions, indicating positive sentiment [5] - ABL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [5] Group 3: Price Target Limitations - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [2][3] - Empirical research indicates that price targets often mislead investors rather than guide them, with analysts sometimes setting overly optimistic targets due to business incentives [3] - A low standard deviation in price targets indicates a high degree of agreement among analysts, which can be a starting point for further research [4]

New partnership leverages PREADISAN™, the cutting-edge health prediction platform using machine learning and modern proteomicsApplies novel big data analytics tools to the Abacus portfolio of servicesLorisco's risk scores will enable a more personalized approach to longevity and actuarial technology to maximize value for Abacus’ clients ORLANDO, Fla and NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity an ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 more than doubled year-over-year to $29.1 million from $11.4 million [16] - Adjusted EBITDA grew 83% year-over-year to $16.7 million, with an adjusted EBITDA margin of 57.5% compared to 80.4% in the prior year [18] - Adjusted net income increased 75% year-over-year to $11.8 million or $0.18 per diluted share [8][18] - Total operating expenses for Q2 2024 were approximately $18.9 million, significantly higher than $1.3 million in the prior year period, influenced by non-cash stock compensation and public company expenses [17] Business Line Data and Key Metrics Changes - Origination capital deployed was $104.7 million, up from $59.8 million in the prior year [15] - Policies purchased increased by 95% to 275 compared to 141 in the prior year period [15] - The company held 458 policies as of June 30, 2024, with 452 accounted for under the fair value method [16] Market Data and Key Metrics Changes - The company established a national distribution relationship with Amcor, enhancing its ability to offer protection and retirement solutions [12] - The acquisition of Carlisle Management Company will add approximately $2 billion in assets under management, while FCF Advisors will add about $600 million [9][11] Company Strategy and Development Direction - The company aims to solidify its position as a leading market maker and global alternative asset manager, targeting nearly $3 billion in assets under management post-acquisitions [7] - Focus on expanding complementary lifespan-based financial products alongside the core business of acquiring life insurance policies [8] - The company is committed to constant innovation through its wealth of longevity and actuarial data [13] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the growth opportunities ahead, leveraging their successful business model and proprietary data [13] - The company anticipates deploying the majority of the raised capital before year-end, potentially as early as Q3 [24] - Management remains optimistic about maintaining strong performance in the second half of the year, despite managing expectations [26] Other Important Information - The company successfully closed an oversubscribed public offering of 11.5 million shares, raising over $90 million [11] - Total originated face value for the quarter was $447 million, with opportunities to acquire policies from other asset managers [31] Q&A Session Summary Question: Can you discuss deployment and capacity for the raised capital? - Management expects to deploy the majority of the raised capital before year-end, potentially as early as Q3, capitalizing on increased policy flow [24] Question: What are the expectations for adjusted EBITDA for the full year? - Management indicated that while Q2 was strong, they want to manage expectations for Q3 and Q4, but overall numbers look positive [26] Question: What was the originated face value in the quarter? - The total originated face value for the quarter was $447 million, with opportunities to acquire policies outside of their origination platform contributing to the high volume [31] Question: How do you see active management revenue trending? - Management believes the active management revenue is sustainable and profitable, with a strong return on equity [32] Question: What is the outlook for M&A activity? - Management will continue to be opportunistic with M&A, focusing on integrating acquired companies successfully [38] Question: What progress has been made on the Abacus Tech front? - ABL Tech continues to grow, adding new clients and providing recurring fee earnings [41] Question: What are the current market opportunities? - Management sees significant market opportunities, with pent-up demand and a broader set of policies available for purchase at better rates [47]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-39403 Abacus Life, Inc. (Exact name of registrant as specified in its charter) Delaware 85-1210472 ...